Literature DB >> 21863346

Is there evidence for late cognitive decline in chronic schizophrenia?

Jharna N Shah1, Salah U Qureshi, Ali Jawaid, Paul E Schulz.   

Abstract

Schizophrenia (SZP) has been historically referred to as "dementia praecox" because of the recognition that its onset is associated with deficits in memory, attention and visuospatial orientation. We wondered whether there is evidence for additional cognitive decline late in the course of chronic SZP. This review examined the evidence (1) for cognitive decline late in the course of chronic SZP, (2) for how often the late cognitive decline occurs, and (3) whether the cognitive decline in late-life SZP is related to pathophysiology of SZP versus the superimposition of another type of dementia. A PUBMED search was performed combining the MESH terms schizophrenia and dementia, cognitive decline, cognitive impairment and cognitive deficits. A manual search of article bibliographies was also performed. We included longitudinal clinical studies employing standard tests of cognition. Cross-sectional studies and those that did not test cognition through standard cognitive tests were excluded. The initial search produced 3898 studies. Employing selection criteria yielded twenty-three studies. Our data extraction tool included the number of patients in the study, whether a control group was present, the age of patients at baseline and follow-up, the study setting (inpatients versus outpatients), the cognitive tests employed, study duration, and results. Only three longitudinal studies tested for dementia using Diagnostic and statistical manual of mental disorder (DSM) or International classification of disease (ICD) criteria and compared them to controls: two studies demonstrated an increase in the prevalence of dementia and one did not. Twenty longitudinal studies tested for one or more cognitive domains without employing standard criteria for dementia: twelve studies demonstrated a heterogeneous pattern of cognitive decline and eight did not. Studies generally did not control for known risk factors for cognitive impairment such as education, vascular risk factors, apolipoprotein (ApoE) genotype and family history. The evidence for late cognitive decline in SZP is mixed, but, slightly more studies suggest that it occurs. If it occurs, it is unclear whether it is related to SZP or other risks for cognitive impairment. Hence, prospective, longitudinal, controlled studies are needed to confirm that there is progressive cognitive decline in chronic SZP which occurs independent of other risk factors for cognitive impairment.

Entities:  

Mesh:

Year:  2012        PMID: 21863346     DOI: 10.1007/s11126-011-9189-8

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  46 in total

1.  Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-year cognitive and functional status.

Authors:  Eran Chemerinski; Abraham Reichenberg; Brian Kirkpatrick; Christopher R Bowie; Philip D Harvey
Journal:  Schizophr Res       Date:  2006-04-19       Impact factor: 4.939

Review 2.  Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.

Authors:  T E Goldberg; D R Weinberger
Journal:  J Clin Psychiatry       Date:  1996       Impact factor: 4.384

Review 3.  Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.

Authors:  H E Spohn; M E Strauss
Journal:  J Abnorm Psychol       Date:  1989-11

4.  Dementia as a complication of schizophrenia.

Authors:  P J de Vries; W G Honer; P M Kemp; P J McKenna
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

5.  Catamnestic long-term study on the course of life and aging of schizophrenics.

Authors:  L Ciompi
Journal:  Schizophr Bull       Date:  1980       Impact factor: 9.306

6.  Cognitive functions and psychopathological symptoms in early-onset schizophrenia.

Authors:  T Banaschewski; E Schulz; M Martin; H Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2000-03       Impact factor: 4.785

7.  Stability and course of neuropsychological deficits in schizophrenia.

Authors:  R K Heaton; J A Gladsjo; B W Palmer; J Kuck; T D Marcotte; D V Jeste
Journal:  Arch Gen Psychiatry       Date:  2001-01

8.  Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality.

Authors:  J L Waddington; H A Youssef; C Dolphin; A Kinsella
Journal:  Arch Gen Psychiatry       Date:  1987-10

9.  Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study.

Authors:  Silvana Galderisi; Michael Davidson; René S Kahn; Armida Mucci; Han Boter; Mihai D Gheorghe; Janusz K Rybakowski; Jan Libiger; Sonia Dollfus; Juan J López-Ibor; Joseph Peuskens; Luchezar G Hranov; Wolfgang W Fleischhacker
Journal:  Schizophr Res       Date:  2009-10-12       Impact factor: 4.939

Review 10.  Should cognitive deficit be a diagnostic criterion for schizophrenia?

Authors:  Ralph Lewis
Journal:  J Psychiatry Neurosci       Date:  2004-03       Impact factor: 6.186

View more
  16 in total

1.  Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders.

Authors:  Stéphane Potvin; Ginette Aubin; Emmanuel Stip
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-06-13       Impact factor: 5.270

2.  Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia.

Authors:  Hans-Gert Bernstein; Susan Müller; Hendrik Dobrowolny; Carmen Wolke; Uwe Lendeckel; Alicja Bukowska; Gerburg Keilhoff; Axel Becker; Kurt Trübner; Johann Steiner; Bernhard Bogerts
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-12-29       Impact factor: 5.270

Review 3.  Neurodegenerative model of schizophrenia: Growing evidence to support a revisit.

Authors:  William S Stone; Michael R Phillips; Lawrence H Yang; Lawrence S Kegeles; Ezra S Susser; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2022-03-25       Impact factor: 4.662

Review 4.  Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Authors:  Jun Ku Chung; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Danielle Uy; Philip Gerretsen; Fernando Caravaggio; M Mallar Chakravarty; Ariel Graff-Guerrero
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-29       Impact factor: 4.105

5.  Estimating the Prevalence of Serious Mental Illness and Dementia Diagnoses Among Medicare Beneficiaries in the Health and Retirement Study.

Authors:  Maria Teresa Brown; Douglas A Wolf
Journal:  Res Aging       Date:  2017-08-31

6.  Health outcomes and cost of care among older adults with schizophrenia: a 10-year study using medical records across the continuum of care.

Authors:  Hugh C Hendrie; Wanzhu Tu; Rebeka Tabbey; Christianna E Purnell; Roberta J Ambuehl; Christopher M Callahan
Journal:  Am J Geriatr Psychiatry       Date:  2013-04-06       Impact factor: 4.105

7.  Sex differences in DEK expression in the anterior cingulate cortex and its association with dementia severity in schizophrenia.

Authors:  Sinead M O'Donovan; Ana Franco-Villanueva; Valentina Ghisays; Jody L Caldwell; Vahraim Haroutunian; Lisa M Privette Vinnedge; Robert E McCullumsmith; Matia B Solomon
Journal:  Schizophr Res       Date:  2018-07-13       Impact factor: 4.939

8.  A commentary on "Antipsychotic-induced Parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders".

Authors:  Amir Salem; Ahmed A Moustafa
Journal:  Front Behav Neurosci       Date:  2015-05-27       Impact factor: 3.558

9.  Severe psychiatric disorders in mid-life and risk of dementia in late- life (age 65-84 years): a population based case-control study.

Authors:  Renate R Zilkens; David G Bruce; Janine Duke; Katrina Spilsbury; James B Semmens
Journal:  Curr Alzheimer Res       Date:  2014       Impact factor: 3.498

10.  A comparison of cognitive performance in the Suffolk County cohort and their unaffected siblings.

Authors:  Kate E Valerio; Katherine G Jonas; Greg Perlman; Evelyn J Bromet; Roman Kotov
Journal:  Psychiatry Res       Date:  2021-07-14       Impact factor: 11.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.